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Extended use of cardiopulmonary bypass (CPB) systems is often hampered by thrombus formation and infection. Part of these
problems relates to imperfect hemocompatibility of the CPB circuitry. The engineering of biomaterial surfaces with genuine long-
term hemocompatibility is essentially virgin territoryin biomaterials science. For example, most experiments with the well-known
Chandler loop model, for evaluation of blood-biomaterial interactions under ﬂow, have been described for a maximum duration
of 2hours only. This study reports a systematic evaluation of two commercial CPB tubings, each with a hemocompatible coating,
and one uncoated control. The experiments comprised (i) testing over 5hours under ﬂow, with human whole blood from 4 diﬀer-
entdonors;(ii)measurementofessentialbloodparametersofhemocompatibility;(iii)analysisoftheluminalsurfacesbyscanning
electron microscopy and thrombin generation time measurements. The dataset indicated diﬀerences in hemocompatibility of the
tubings.Furthermore,itappearedthatdiscriminationbetweenbiomaterialcoatingscanbemadeonlyafterseveralhoursofblood-
biomaterial contact. Platelet counting, myeloperoxidase quantiﬁcation, and scanning electron microscopy proved to be the most
useful methods. These ﬁndings are believed to be relevant with respect to the bioengineering of extracorporeal devices that should
function in contact with blood for extended time.
Copyright © 2007 Kris N. J. Stevens et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Cardiopulmonary bypass (CPB) technology represents one
of the most striking examples of progress in biomedical en-
gineering. Procedures in cardiac surgery that rely on CPB
can nowadays be regarded as safe, that is, they are associated
with a low incidence of mortality [1–3]. These developments
resulted, to a signiﬁcant extent, from improvements in the
polymeric biomaterials that constitute the inner surface of
CPB circuits. Within CPB circuits, there is extensive blood
contactwiththetubing,thepump,and,particularly,theoxy-
gen/carbon dioxide exchange membrane. It is well known
that cellular components of the blood (particularly, leuko-
cytes and platelets) may become activated, and that four
diﬀerent but partially overlapping plasma protein cascades
will go into operation (intrinsic and extrinsic clotting cas-
cade, complement system, and ﬁbrinolytic protein system)
[4]. For more than 4 decades, heparin has been used as the
standard“anticoagulant”tocounterbalancetheseeﬀects.Im-
provements resulted from the use of surface coatings expos-
ing heparin at the blood-biomaterial interface. These coat-
ings reduce coagulation, inﬂammation, complement activa-
tion,andplateletactivation[2,4].Morerecently,CPBequip-
ment has been coated with poly(2-methoxy-ethylacrylate)
(PMEA), based on the hypothesis that this material leads
to improved blood compatibility compared to uncoated sur-
faces. PMEA is cheap compared to heparin-exposing coat-
ings and was postulated to provide a useful alternative for
patients with heparin-associated disorders [5–7].
However, serious complications may arise if extracorpo-
real circulation has to be sustained, that is, for several days.
The most frequent problems stem from bacterial infection,
hemolysis, thrombus formation within the circuit, and for-
mation of circulating thrombotic emboli [8–10]. We became2 Journal of Biomedicine and Biotechnology
intrigued by these problems, since they relate to long-term
hemocompatibility of polymeric materials, which is in fact
unexplored territory in biomaterials science. Indeed, we no-
ticed that the literature on blood compatibility of CPB cir-
cuits merely contains experimental data that correspond to
short testing periods. For example, Weber et al. extensively
studied hemocompatibility of 4 diﬀerent biomaterials in a
CPB model, but only up to 120 minutes [11]. We adhere to
the idea that successful development of novel biomaterials or
biomaterial coatings for CPB will depend on robust evalua-
tion models in which the blood-biomaterial contact is main-
tained for several hours at least.
Herein we report a systematic methodological study
in which two commercial surface-coated CPB tubings
(heparin-coated tubings and PMEA-coatedtubings) and one
uncoated control were evaluated in contact with human
whole blood under ﬂow, for a period of 5 hours. We cal-
culated that 5 hours of experimentation implies a level of
blood-biomaterial contact that corresponds to at least 9
hours of operation in a typical CPB system (vide infra). Sev-
eral assays were used to evaluate the blood (platelet counts
and assays to determine hemolysis, platelet activation, leuko-
cyte activation, and activation of the complement system).
Scanning electron microscopy (SEM) was used to study de-
position of blood components at the surface of the tubings.
A full set of data was acquired for the three diﬀerent mate-
rials, four donors and ﬁve time points (0, 75, 150, 225, and
300 minute). The three materials showed clear diﬀerences,
in general pointing towards an inferior hemocompatibility
of the PMEA coating. Moreover, two points with respect
to bioengineering of improved coatings for long-term CPB
emerged as follows: (i) since most of the diﬀerences between
the three surfaces did not become apparent during the ﬁrst
2 hours of experimentation, long-term (e.g., 5 hour) test-
ing of blood-biomaterial interactions under ﬂow is required;
(ii) preferably, parallel tests with blood from several diﬀerent
donors should be performed, since the results from several
assays appeared to be clearly donor-dependent.
2. MATERIALS AND METHODS
2.1. Materials
Polyvinyl chloride (PVC) tubings with a coating of PMEA
were a generous gift of Terumo Europe NV (Leuven, Bel-
gium). The internal diameter of the tubings was 0.476cm.
The same company also provided the uncoated tubings
with identical internal diameter, which were used as con-
trols. Tubings with a coating of heparin were obtained from
Maquet Cardiopulmonary AG (Hirrlingen, Germany). The
internal diameter was also 0.476cm. All tubings were re-
ceived in a sterile package and cut to length of (42.5cm)
immediately prior to the experiments. Lepirudin (Reﬂu-
dan) was purchased from Pharmion (Windsor Berkshire,
UK). Bovine serum albumin (BSA), Na-citrate, ethylene-
diaminetetraacetic acid (EDTA), and Zymosan A were
from Sigma-Aldrich Chemie B.V. (Zwijndrecht, The Nether-
lands). 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), NaCl, KCl, and Glutaraldehyde 25% were from
Acros Organics (Geel, Belgium). Na2HPO4 and KH2PO4
werefromJanssenChimica(Beerse,Belgium).Ethanol100%
was from Merck KGaA (Darmstadt, Germany). The chro-
mogenic substrate S2238 was synthesized according to Ri-
jkers et al. [12]. The following solutions were prepared: a
lepirudin stock solution (lepirudin 200 μg/mL, NaCl 9g/L),
a HEPES/EDTA stock solution (HEPES 100mM, EDTA
40mM, pH 7.4), a phosphate-buﬀered saline (PBS) solu-
tion (NaCl 8 g/L, KCl 0.2g/L, Na2HPO4 1.44g/L, KH2PO4
0.24g/L, pH 7.4), a CaCl2 s t o c ks o l u t i o n( 0 . 5 MC a C l 2), a
Na-citrate stock solution (Na-citrate 0.13M), an S2238 stock
solution (S2238 2mM), and a stop buﬀer (NaCl 140mM,
HEPES 20mM, EDTA 20mM, BSA 1mg/mL, S2238 stock
solution 1/10, pH 7.5). Citrate, theophylline, adenosine,
dipyridamole (CTAD) stock solution (BD Vacutainer CTAD
Tubes) was a product from Becton Dickinson (Alphen
aan den Rijn, The Netherlands). The enzyme-linked im-
munosorbent assay (ELISA) for β-thromboglobulin (β-TG)
(Asserachrom β-TG) was purchased from Diagnostica Stago
(Asni` eres sur Seine, France) and ELISA kits for terminal
complement complex (TCC) and myeloperoxidase (MPO)
were from Hycult biotechnology B.V. (Uden, The Nether-
lands).
2.2. Equipment
Experiments were performed on a modiﬁed Chandler loop
system,whichwasequippedwithabroadwheelwithadiam-
eter of 13cm [13]. On this wheel, 12 tubes could be rotated
simultaneously. The rotating speed was set at 32 per minute.
The rotating wheel and the mounted tubes were immersed
in a water bath that was kept at 37◦C throughout the en-
tire experiment. The Chandler loop device was made by the
mechanical workshop of the Instrument Development Engi-
neering & Evaluation of the University Maastricht. Centrifu-
gation was performed with an Eppendorf Centrifuge 5417C
(Eppendorf, Hamburg, Germany). Platelets were counted
on an automatic cell counter (Coulter AC-T diﬀ,B e c k -
man Coulter, Miami, Fl, USA). The absorbance of plasma-
free hemoglobin (Hb) was determined on a spectropho-
tometer (Multiskan Spectrum Microplate Spectrophotome-
ter, Thermo Labsystems, Vantaa, Finland). Microtiter plates
were heated on a plate warmer (Single Micro-Hywel, Chro-
mogenix, Milano, Italy). For both the ELISA assays and the
thrombin generation time assay, the absorbances of the mi-
crotiter plates were determined spectrophotometrically on a
microplate reader (ELx808 Absorbance Microplate Reader,
BioTek Instruments, Inc., Vt, USA). Samples for SEM were
coated with gold on a sputter coater (Sputter coater 108
auto/SE, Cressington Scientiﬁc Instruments Ltd., Watford,
UK) and then analyzed with a scanning electron microscope
(Philips XL30 Scanning Electron Microscope, Philips, Eind-
hoven, The Netherlands).
2.3. Experimentsunderﬂowconditions:
theChandlerloopmodel
This study was approved by the Ethical Committee of the
University of Maastricht. Four healthy male blood donorsKris N. J. Stevens et al. 3
(further indicated by their initials as WW, KS, SB, and JB)
aged between 20 and 25 years old were included in this study.
They were all nonsmokers and did not take any haemostasis-
inﬂuencing medicines at least 10 days before the experiment.
Each donor visited our laboratories twice and donated blood
for two diﬀerent experiments; there were at least 7 days be-
tween the two visits.
2.3.1. Hemocompatibilityanalysisbyplateletcounting
andassessmentofhemolysis(performedafterthe
ﬁrstvisitofeachdonor)
Blood was withdrawn by venipuncture and immediately an-
ticoagulated with lepirudin stock solution (1 part lepirudin
stock solution and 9 parts whole blood), following recom-
mendations made by Kopp et al. [14]. Directly after blood
collection, 1.35mL of blood was sampled and processed as
describedfurthertoobtainbaselinevalues.Next,threediﬀer-
ent tubes (one heparin-coated tube, one PMEA-coated tube,
and one uncoated control tube) were each ﬁlled with 6.7 mL
wholeblood,whichcorrespondstoadegreeofﬁllingof88%.
The tubes were then closed end-to-end using silicon sleeves,
mounted on the rotating wheel, and rotated in a water bath
at 37◦Ca n d3 2r p m .
From each tube, 1.35mL blood was withdrawn after 75,
150, 225, and 300 minutes of incubation; note that in the
tubes, the degree of ﬁlling gradually dropped from 88%,
via 70% and 53%, to 35%. Immediately after withdrawal
from the tube, each blood sample was mixed with 150μL
HEPES/EDTA stock solution. One third of this mixture
(500μL) was used for platelet counting; these counts were
performed intriplicate.
The other part of the HEPES/EDTA-mixed blood sam-
ple (1mL) was processed for assessment of hemolysis. The
percentage of plasma-free Hb was used as an indicator for
hemolysis. 25μL of HEPES/EDTA-mixed blood sample was
diluted 40 times with 975μL deionized water to achieve total
hemolysis. The other 975μL of HEPES/EDTA-mixed blood
sample was kept undiluted. Both the diluted and undiluted
parts were centrifuged (3220g, 20 minutes, 4◦C) to obtain
plasma. Subsequently, the absorbance was measured at three
wavelengths(560,576,and592nm)inplasmaofboththedi-
luted and undiluted parts of the HEPES/EDTA-mixed blood
sample. The percentage of plasma-free Hb was then calcu-
lated for each blood sample according to the procedure of
Cripps [15].
2.3.2. Hemocompatibilityanalysisbyquantiﬁcationof
bloodactivationmarkersviaELISAandSEMofthe
tubeinnersurfaces(performedafterthesecond
visitofeachdonor)
Blood was withdrawn by venipuncture and immediately an-
ticoagulated with lepirudin stock solution (1 part lepirudin
stock solution and 9 parts whole blood), following recom-
mendations made by Kopp et al. [14]. Immediately after
bloodcollection,a4.5mLand1.8mLbloodsamplewereiso-
lated and processed as described further to obtain baseline
values. Next, twelve tubes (four heparin-coated tubes, four
PMEA-coated tubes, and four uncoated control tubes) were
each ﬁlled with 6.7mL whole blood, which corresponds to
a degree of ﬁlling of 88%. The tubes were then closed end-
to-end using silicon sleeves, mounted on the rotating wheel,
and rotated in a water bath at 37◦Ca n d3 2r p m .
After 75, 150, 225, and 300 minutes of incubation, each
time three tubes (one heparin-coated tube, one PMEA-
coated tube and, an one uncoated control tube) were re-
moved from the rotating wheel. Two blood samples were
isolated from each tube: 4.5mL blood was withdrawn and
immediately mixed with 0.5mL CTAD stock solution, and
1.8mL of blood was withdrawn and immediately mixed with
0.2mL HEPES/EDTA stock solution. Both the CTAD-mixed
and HEPES/EDTA-mixed blood were incubated on ice for
15 minutes. Then, plasma was isolated by two subsequent
centrifugation steps (2550g, 20 minutes, 4◦C). The plasma
was aliquoted and stored at −80◦C until further analysis.
ELISA was used to evaluate activation of leukocytes, com-
plement, and platelets. As a marker for leukocyte activa-
tion the levels of MPO were quantiﬁed in HEPES/EDTA-
stabilized plasma. The concentration of β-TG in CTAD-
stabilized plasma served as a marker for platelet activa-
tion. Complement activation was investigated by measuring
plasma concentrations of TCC in HEPES/EDTA-stabilized
plasma. Zymosan A activated whole blood was used as a pos-
itive control for complement activation.
Following isolation of the blood samples, each tube was
prepared for SEM analysis. Nonadherent blood components
were washed away by rinsing the tubes extensively with 25
volumes of PBS solution. Next, adherent blood components
were ﬁxed by incubating the tubes overnight in 2.5% glu-
taraldehyde at 2–8◦C. Fixed samples were dehydrated by
immersion in an ethanol series (50, 70, 80, 95, and 100%
ethanol). Following dehydration, the samples were air-dried.
For each time point, three pieces of air-dried tubing with a
length of 1cm were cut out. The pieces were then cut length-
wise for analysis of the inner surface. This was done for all
donors. Finally, the samples were sputter coated with gold
and imaged with a scanning electron microscope.
2.4. Experimentsunderstaticconditions:thrombin
generationtimeassay
This assay was carried out as described previously [16–
19]. Brieﬂy, blood was withdrawn by venipuncture from a
healthy, nonsmoking male blood donor who did not take
any haemostasis-inﬂuencing medicines at least 10 days be-
fore the experiment. The blood was immediately anticoagu-
lated with citrate stock solution( 1p a r tc i t r a t es t o c ks o l u t i o n
and 9 parts whole blood) and kept at 37◦C until the start
of the experiment. Uncoated, heparin-coated and PMEA-
coated PVC tubes were cut to a length of 5.5cm. These pieces
were closed at one end with a tube clamp. At the start of
the experiment, blood was recalciﬁed with 40μLC a C l 2 stock
solution per mL blood. Subsequently, 750μL of blood was
added to each tube sample and the tube samples were in-
cubated at 37◦C under static conditions. After 5 minutes of
incubation, 17.5μL of blood was taken from each tube sam-
ple and mixed with 282.5μLs t o pb u ﬀer. Sampling was done4 Journal of Biomedicine and Biotechnology
every 5 minutes until 24 minutes of incubation, from then
samplesweretakenevery2minutes.Bloodsampleswerekept
on ice until further handling. At the end of the experiment,
the blood samples were centrifuged at 10621g for 5 min-
utes. Next, 200μL plasma of each sample was loaded onto
a microtiter plate that was kept on ice. After loading, the
microtiter plate was heated for 5 minutes at 37◦C. Finally,
thrombin concentrations were measured using absorption
spectrophotometry at 405nm.
2.5. Statistics
Statistical analysis was performed using Mann-Whitney
analysis for between-group comparisons and the Wilcoxon
test for paired observations for comparison within groups. A
P-value less than .05 (two-tailed) was considered signiﬁcant.
3. RESULTS AND DISCUSSION
3.1. Analysisofthebloodsamples
3.1.1. Plateletcounts
Figure 1 compiles the results on the platelet count experi-
ments; note that data referring to the three diﬀerent bio-
materials, based on blood from four diﬀerent donors and
measured at ﬁve time points, are combined. This format is
used consistently throughout this article. At the start of the
experiment, the donors had platelet counts between 75,000
and 180,000 per μL, which is within the normal range. Some
increased spreading is noted, especially in the counts that
were measured after 225 or 300 minutes. The heparin-coated
specimens and the uncoated controls show invariant platelet
countsasafunctionoftime.ThePMEAcoating,ontheother
hand, induces a decrease in the concentration of circulating
platelets. For donor JB, this eﬀect can be noticed already af-
ter 75min, and the decrease goes on during the entire ex-
periment. For the other donors, platelet counts start to de-
cline only after 150 minutes (KS and SB), or after 225 min-
utes(WW).Thelargestdropinplateletcountwasfoundwith
the blood from donor JB in the PMEA-coated tube; the con-
centration of circulating platelets decreased by almost 60%,
from ca. 140,000 per μL to ca. 60,000 per μL. At the end of
theexperiment,theconcentrationofcirculatingplateletswas
signiﬁcantly lower in the PMEA-coated tubes compared to
the heparin-coated tubes (79,917 ± 6,304 platelets/μL blood
for PMEA-coated tubes versus 135,333 ± 10,623 platelets/μL
blood for heparin-coated tubes (mean ± sem), see Table 1
(supplementary material), P = .001) and the uncoated con-
trols (79,917 ± 6,304 platelets/μL blood for PMEA-coated
tubes versus 133,833 ± 10,650 platelets/μL blood for un-
coated controls (mean ± sem), see Table 1 (supplemen-
tary material), P = .001). This indicated that the PMEA
coating has a propensity to activate contacting platelets.
This is, most probably, not a direct eﬀect, but an eﬀect of
plasma proteins adsorbed onto the PMEA surface. Activated
platelets are known to adhere to adsorbed ﬁbrinogen, von
Willebrand factor, vitronectin, and ﬁbronectin [20]. Conse-
quently, this results in lower platelet counts. In addition, ac-
tivated platelets adhere to each other via ﬁbrinogen bridges,
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Figure 1: Platelet counts for the individual donors. Data are shown
at ﬁve time points for each tubing surface tested. Measurements
were performed in triplicate.
anchored by GPIIb/IIIa receptors [21]. Activated platelets
also adhere to circulating leukocytes [22, 23]. Some of the
surface-attached platelets partially detach, leaving adherent
membrane fragments [24]. Other platelets are damaged by
shear forces [25]. Recently, platelet counts were also used in
a clinical study to evaluate hemocompatibility of heparin-
and PMEA-coated CPB circuits. Kutay et al. reported a more
signiﬁcant depletion of circulating platelets in PMEA-coated
circuits compared to heparin-coated circuits [26].
3.1.2. Hemolysis
Figure 2 shows the dataset resulting from our concentration
measurementsofextracellular(free)Hb.Ruptureoferythro-
cytes (hemolysis) (e.g., due to collisions with the lumen of
the tubes) leads to release of Hb into the plasma. The vertical
axis in Figure 2 depicts the ratio free Hb : total Hb, expressed
as a percentage. Clearly, hemolysis is very low, that is, most
of the erythrocytes remained intact in all cases. Even in the
most extreme situation (donor JB, PMEA coating, 300 min-
utescirculation),only1outofevery400moleculesHbisfree.
Despite the occurrence of little hemolysis, it is clear that the
level of free Hb in the plasma increases with circulation time,
which was expected. The three coatings do not perform dif-
ferently in this respect. No signiﬁcant diﬀerences in the levels
of plasma-free Hb were found between the diﬀerent tubes.
The hemolysis assay applied in this study was based on the
Cripps method to measure levels of plasma-free Hb [15]. In
a study by Malinauskas [27], this method was shown to be
more precise and accurate than the chemical addition meth-
ods to measure levels of plasma-free Hb.
3.1.3. Activationofplatelets:β-thromboglobulin
Figure 3 provides an overview of the concentration mea-
surements of β-TG, which is a soluble marker for plateletKris N. J. Stevens et al. 5
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Figure 2: Percentage of plasma-free Hb for the individual donors.
Data are shown at ﬁve time points for each tubing surface tested.
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Figure 3: Concentrations of β-thromboglobulin for the individual
donors. Data are shown at ﬁve time points for each tubing surface
tested. Measurements were performed in duplicate.
activation [28]. Activated platelets release β-TG from their
α-granules.
The β-TG concentration versus time proﬁles show an in-
creasing trend, revealing that platelet activation progresses
with time. With the blood of the donors WW and SB, this
is found consistently for all coatings. The blood of donor JB
follows this pattern, except in contact with PMEA: the con-
centration of β-TGthenremainsvirtuallyunchanged.Thisis
remarkable, since the platelet counts for this donor and this
coating were found to decrease sharply (see Figure 1). Most
likely, platelets of this donor adhere to PMEA without subse-
quent release of the granular contents. Donor KS is slightly
aberrant. The levels of β-TG are relatively high, throughout
all experiments, but it must be kept in mind that this donor
also had the highest platelet counts (see Figure 1). In contact
with the PMEA coating, a steep increase of the concentra-
tion of β-TG is found after 150 minutes of incubation. How-
ever, there were no signiﬁcant diﬀerences in platelet activa-
tion levels between uncoated, heparin-coated, and PMEA-
coated tubes. This indicates that immobilization of heparin
or coating with PMEA does not help to reduce platelet acti-
vation within blood that contacts a PVC surface.
3.1.4. Activationofleukocytes:myeloperoxidase
During ECC, contact between the blood and artiﬁcial sur-
faces is known to induce an inﬂammatory response char-
acterized by the activation of various leukocyte cell types
[23, 29]. Of the various leukocytes, neutrophils are the most
abundant; they play a central role in the inﬂammatory re-
sponse to CPB [27]. MPO is a glycoprotein abundantly
present in the primary granules of neutrophils; activated
neutrophils release MPO by degranulation [23, 30, 31].
Figure 4 presents the data of the concentration measure-
ments of MPO. A clear pattern emerging from the data is
that for every donor, the concentration of MPO increases
continuously. The rise in MPO levels was the highest in
PMEA-coated tubes. This resulted in signiﬁcantly higher lev-
elsofMPOcomparedtoheparin-coatedtubes,attimepoints
225 minute (163 ± 11.6ng/mL for PMEA-coated tubes ver-
sus 131.5 ± 4.8ng/mL for heparin-coated tubes (mean ±
sem), see Table 1 (supplementary material), P = .01) and
300 minute (222.3±11.5ng/mLforPMEA-coatedtubesver-
sus 157.7 ± 3.6ng/mL for heparin-coated tubes (mean ±
sem), see Table 1 (supplementary material), P = .001), and
to uncoated controls, at time point 300 minute (222.3 ±
11.5n g / m Lf o rP M E A - c o a t e dt u b e sv e r s u s1 7 6 .8±9.8ng/mL
for uncoated controls (mean ± sem), see Table 1 (supple-
mentary material), P = .01). These data indicate that the
PMEA coating induces MPO release more abundantly as
compared to both other surfaces. It is of interest to compare
ourdatawitharecentstudyofLappeg˚ ardetal.whoalsoused
the Chandler loop model to investigate neutrophil activation
after blood-artiﬁcial surface contact [23, 29]. After 4 hours
of blood circulation they found signiﬁcantly lower levels of
MPO release in heparin-coated tubes compared to uncoated
controls. Lappeg˚ ard et al., however, used a heparin coating
based on covalently end point-attached heparin [29], while
the heparin coating used in our experiments involved both
covalent and ionic interactions of heparin with the surface.
Our results appear to be in line with a recent clinical
study by Kutay et al. who compared the hemocompatibility
of PMEA- and heparin-coated CPB [26]. MPO levels at the
endofCPBweresigniﬁcantlyhigherinthePMEA-coatedcir-
cuits compared to the heparin-coated circuits. Besides MPO,
plasma levels of interleukin-8, a proinﬂammatory cytokine,
were also quantiﬁed by ELISA. In the three diﬀerent tubes,
plasma levels of interleukin-8 remained undetectable until
225 minutes of incubation. At the end of the experiment,
interleukin-8 generation did not diﬀer signiﬁcantly between
the three tubes and plasma levels never exceeded 90pg/mL
(data not shown). Apparently, 5 hours of blood-biomaterial6 Journal of Biomedicine and Biotechnology
0 75 150 225 300
Control
0 75 150 225 300
Heparin
Time (min)
0 75 150 225 300
PMEA
0
50
100
150
200
250
300
[
M
P
O
]
(
n
g
/
m
L
)
WW
KS
SB
JB
Median
Figure 4: Concentrations of myeloperoxidase for the individual
donors. Data are shown at ﬁve time points for each tubing surface
tested. Measurements were performed in duplicate.
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Figure 5: Concentrations of terminal complement complex for the
individual donors. Data are shown at ﬁve time points for each tub-
ing surface tested. Measurements were performed in duplicate. As
can be seen, TCC was undetectable in all samples at time point 0
hour.
contact in our model are not suﬃcient to use interleukin-8
as a discriminating marker for inﬂammatory responses.
3.1.5. Activationofthecomplementsystem:terminal
complementcomplex
Complement activation has been studied extensively as a
marker for hemocompatibility of artiﬁcial surfaces. Diﬀer-
ent components of the complement activation cascade can
be used [31]. However, in a study by Gong et al. [32], gen-
eration of complement activation products in the Chan-
dler loop model displayed component-speciﬁc responsive-
ness to the size of the gas surface and the biomaterial sur-
face. Of the complement activation markers evaluated, gen-
eration of TCC was least inﬂuenced by the size of the gas
surface and mainly dependent on the biomaterial surface.
This prompted us to use TCC as a complement activation
marker in our study. Figure 5 depicts the data of the concen-
tration measurements of TCC. The levels of TCC were unde-
tectable at the start of the experiments but increased steadily
in all tubes throughout the experiment. At several time
points, signiﬁcantly higher levels of TCC could be detected
in heparin-coated tubes compared to PMEA-coated tubes
(at 75 minute: 7.5 ± 0.8AU/mL for heparin-coated tubes
versus 4.8 ± 0.2AU/mL for PMEA-coated tubes (mean ±
sem), see Table 1 (supplementary material), P = .001; at 150
minute: 11.5 ± 1.4 AU/mL for heparin-coated tubes versus
7.9 ± 0.4AU/mL for PMEA-coated tubes (mean ± sem), see
Table 1 (supplementary material), P = .024; at 225 minute:
14.7 ± 1.3AU/mL for heparin-coated tubes versus 11.1 ±
0.7AU/mL for PMEA-coated tubes (mean ± sem), see Table
1 (supplementary material), P = .027) and uncoated controls
(at 75 minute: 7.5±0.8AU/mL for heparin-coated tubes ver-
sus 5.9 ± 0.7AU/mL for uncoated controls (mean ± sem),
see Table 1 (supplementary material), P = .036). This sug-
gests that TCC generation proceeds faster in heparin-coated
tubes compared to PMEA-coated tubes and uncoated con-
trols. Several in vitro studies using the Chandler loop model
reported prevention of TCC generation by heparin-coated
P V Cc o m p a r e dt ou n c o a t e dP V C[ 20, 23, 29, 33]. However,
none of these studies had blood circulation times of more
than two hours. Also, these studies used heparin coatings
which were structurally diﬀerent from the heparin coating
evaluated in our study. Weber et al. compared covalently
heparin-coated tubes from four diﬀerent manufacturers and
a l s of o u n dm a r k e dd i ﬀerences in hemocompatibility [11].
3.2. Analysisoftheinnersurface
3.2.1. Scanningelectronmicroscopy
A set of scanning electron micrographs was recorded (3 dif-
ferent materials, 4 donors, 5 diﬀerent times of circulation
in the Chandler loop system, and three samples of every
tube were examined). In general, we observed that adhe-
sion of blood components developed slowly and gradually as
the experiments proceeded. However, the SEM data revealed
a striking diﬀerence between uncoated PVC and heparin-
coated PVC on one hand, and the PMEA-coated PVC on the
other hand. Four micrographs, taken after 5 hours of blood
circulation over the surfaces, are shown in Figure 6 to illus-
trate this diﬀerence. The uncoated PVC and heparin-coated
PVC surfaces showed a remarkable resemblance. These sur-
faces were, to an extent of approximately 80%, devoid of
any visible adherent blood components. There were, how-
ever, island-like regions, usually small (e.g., 10 × 10μm)
but sometimes larger (e.g., 100 × 200μm). Enlarged im-
ages of these islands (see Figures 6(a) and 6(b)) revealed
a ﬂat patch-like structure, presumably composed of ﬁbrinKris N. J. Stevens et al. 7
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Figure 6: (a) Scanning electron micrograph of a typical island structure on the inner surface of the uncoated (control) tube, after 5 hours
contact with full human blood in the Chandler loop model. A patch-like structure is seen, which is, presumably, composed of ﬁbrin threads,
which adhered to the surface. (b) Scanning electron micrograph of a typical island structure on the inner surface of the heparin-coated tube
(same conditions). The patch-like structures in (a) and (b) are similar; note that platelets as well as cells (presumably leukocytes) are seen in
(b). (c) Scanning electron micrograph of the PMEA-coated surface, after 5 hours of experimentation in the Chandler loop. Adhered cells are
observed, either individually, or in small aggregates of 2 or 3 cells. Cells and aggregates are, to a good approximation, evenly spread over the
surface, although regions of relatively high cell density could be discerned. (d) Close-up on a region of relatively high cell density. Note that
most of the adherent cells are engaged into cell-cell contacts through pseudopodia.
threads. Some blood platelets were entrapped in the patch,
in the case of the uncoated surface (see Figure 6(a)). For
the heparin-coated surface, platelets as well as larger cells
(presumably leukocytes) were entrapped in or adhered to
the patch structure (see Figure 6(b)). Evaluation of the in-
ner surface of the PMEA-coated tubing showed radically dif-
ferent pictures as can be seen in Figures 6(c) and 6(d).F i b -
rin formation is evident on the uncoated and heparin-coated
surfaces, but not for the PMEA-coating. Scattered over the
PMEA-coated surface, we encountered isolated cells, or en-
sembles of a small number of cells (typically 2 or 3 cells).
Presumably, the adhered cells are leukocytes; the diameter of
these cells is 10–15μm. Figure 6(d) shows a detailed SEM
micrograph of a region that was relatively densely popu-
lated with adherent cells. It is seen that most of the cells
extend pseudopodia, through which they are connected to
oneormoreneighbors. Leukocyteactivationinduced bysur-
face contact, leading to pseudopodia (see Figure 6(d)), can
also explain why the MPO concentration was highest for the
PMEA-coated PVC tube as compared to the other two tubes
(see Figure 4).
3.2.2. Measurementofthrombingenerationtimes
Inviewofthediﬀerencesbetweenthesecoatingsencountered
after prolonged blood contact in the Chandler loop, we de-
cided to subject the surfaces also to the well-known throm-
bingenerationassay[16–19].Contactactivationoftheblood
coagulation system is accompanied by a sudden increase of
thrombin levels, after a lag-time that varies between approxi-
mately 5 minutes for highly thrombogenic materials to ap-
proximately 60 minutes for materials with extremely low
thrombogenicity. Figure 7 shows the thrombin generation
curves measured in triplicate with the uncoated, heparin-
coated, and PMEA-coated PVC tubes. Thrombin genera-
tion occurred between 30 and 40 minutes in the uncoated
PVC tubes. Coating of the PVC with immobilized heparin
prolonged the thrombin generation time until 60 minutes.
This clearly indicates the better antithrombogenic proper-
ties of the heparin-coated PVC tubes compared to uncoated
PVC tubes. A remarkable ﬁnding, however, was that coat-
ing of PVC tubes with PMEA resulted in thrombin genera-
tion times comparable to those of the uncoated PVC tubes.
Note that, in the case of the heparin-coated PVC, the throm-
bin concentration remains <2nM, even after 60 minutes.
The analysis was stopped after this time point since the as-
say is static. The red blood cells may show aberrant behav-
ior after 1 hour of static conditions (Rouleaux formation),
which compromises the reliability of the method. Compar-
ingthethrombingenerationcurves,weconcludethatthrom-
bogenicity of the three diﬀerent surfaces is as follows: un-
coated PVC ≈ PMEA-coated PVC > heparin-coated PVC.8 Journal of Biomedicine and Biotechnology
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Figure 7: Thrombin generation curves measured for uncoated PVC (a), heparin-coated PVC (b), and PMEA-coated PVC (c) incubated with
recalciﬁed blood under static conditions. Experiments were performed in triplicate, that is, every blood sample was analyzed three times.
3.2.3. TheChandlerloopmodel
After collecting all data, we wondered whether any cor-
relation could be deﬁned between the intensity of blood-
biomaterial contact in the Chandler loop system, and that
in real-life extracorporeal circulation in CPB. Assuming that
the level of blood-biomaterial contact (Q) is proportional to
the surface area of the artiﬁcial material (S) and the time of
blood-biomaterial contact (t), and inversely proportional to
the blood volume (V), it can be calculated for the Chandler
loop system (with S = 40cm2, V = 7mL,t = 5h), that Q =
28.6h/cm. For a typical CPB system (with S = 25,000cm2, V
= 8,000mL (6L of blood + 2L of priming ﬂuid)), it then fol-
lows that t = (28.6 × 8,000)/25,000 ≈ 9h. In other words,
this simple model indicates that 5 hours of experimenta-
tion in the Chandler loop corresponds with a level of blood-
biomaterial contact that corresponds to at least 9 hours of
operation in a typical CPB system. Most probably, the esti-
mated 9 hours is an underestimation, since the blood cells
in real-life CPB are oxygenated and the blood resides mostly
within the patient’s vasculature. This probably implies that
some recuperation of blood cells occurs during real-life CPB,
while this is evidently not the case in our model system.
Noteworthy, the extent of hemolysis encountered in our ex-
periments was very low, that is, <0.3% after 5 hours of circu-
lation, irrespective of the donor or (coated) surface.
4. CONCLUSION
Systematic evaluation of the blood biomaterial contact for
the three diﬀerent tubings, using relatively long periods of
blood-biomaterial contact, was performed. The three dif-
ferent surfaces were as follows: uncoated PVC, heparin-
coated PVC, and PMEA-coated PVC; the latter two are al-
ready in clinical use, as tubings in extracoporeal circula-
tion equipment. Clear diﬀerences with respect to platelet
counts, leukocyte activation (MPO release), and deposition
of blood components at the inner surfaces were found. MostKris N. J. Stevens et al. 9
of these diﬀerences became apparent only after the ﬁrst 2–
3 hours of experimentation. This underlines the importance
of extended evaluation of blood-contacting biomaterials that
are to be used in long-term applications, such as extended
CPB. It is noteworthy that the PMEA-coated tubes showed
a relatively low level of hemocompatibility. Compared with
uncoated PVC and heparin-coated PVC, (i) a substantial
drop of the platelet counts, (ii) activation of leukocytes and
marked adherence of leukocytes at the inner surface, and
(iii) a thrombogenicity comparable to uncoated PVC were
observed. The present results lead to two important conclu-
sions.
(1) The Chandler loop system is the most useful method
for the evaluation of blood-biomaterial interactions,
w h i c hi sm o s tp r o b a b l yr e l e v a n tf o rt h ed e v e l o p m e n t
of equipment for extracorporeal circulation. Extended
experimentation times (e.g., 5 hours) are mandatory,
since diﬀerences for various materials may masquer-
ade during the ﬁrst few hours.
(2) PMEA biomaterial is probably not optimal for use
in extracorporeal circulation equipment; further im-
provements are necessary.
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